• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients With Atrial Fibrillation
ConclusionsOlder adults with atrial fibrillation rarely have absolute contraindications to oral anticoagulation therapy. Among patients without contraindications, most appeared to be eligible for any anticoagulant, and relatively high‐risk features appeared not to influence warfarin use.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - April 1, 2015 Category: Cardiology Authors: Benjamin A. Steinberg, Melissa A. Greiner, Bradley G. Hammill, Lesley H. Curtis, Emelia J. Benjamin, Susan R. Heckbert, Jonathan P. Piccini Tags: Original Research Article Source Type: research

The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial
Summary Acute coronary syndrome (ACS) is a medical emergency often associated with an occlusive coronary event with consequent myocardial underperfusion. Patients require immediate antiplatelet therapy and long‐term antithrombotic prophylaxis to reduce the risk of recurrence. Acetylsalicylic acid (ASA) alone or in combination with a platelet P2Y12 inhibitor (dual antiplatelet therapy [DAPT]) has become the clinically accepted antithrombotic prophylaxis for patients post‐ACS. Historically, studies assessing the utility of adding oral anticoagulants (OACs) have not demonstrated a clinical benefit with regard to acceptabl...
Source: Cardiovascular Therapeutics - September 9, 2014 Category: Cardiology Authors: Marc Cohen, Deepa Iyer Tags: Review Source Type: research

The ‘Dual‐Pathway’ Strategy After Acute Coronary Syndrome: Rivaroxaban and Anti‐platelet Agents in the ATLAS ACS 2‐TIMI 51 Trial
This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - June 1, 2014 Category: Cardiology Authors: Marc Cohen, Deepa Iyer Tags: Unsolicited Review Source Type: research

Bivalirudin use and one‐month outcome in the context of contemporary antiplatelet treatment: Insights from the Greek Antiplatelet Registry
ConclusionsIn a ‘real life’, contemporary antiplatelet treatment registry, clinical, laboratory and logistic factors affect bivalirudin's choice, while there are no differences in one‐month outcome between bivalirudin and no bivalirudin treated patients.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - February 1, 2014 Category: Cardiology Authors: Dimitrios Alexopoulos, Ioanna Xanthopoulou, Spyridon Deftereos, George Sitafidis, Ioannis Kanakakis, Michalis Hamilos, George Karayannis, Christos Angelidis, Katerina Stavrou, Manolis Vavuranakis, John A. Goudevenos, Christodoulos Stefanadis, Tags: Original Research Article Source Type: research

Ischemic stroke and intestinal bleeding under dabigatran in metabolic myopathy
ConclusionsIschemic stroke and intestinal bleeding may consecutively occur shortly after stopping dabigatran. Coagulation parameters may remain abnormal even two days after discontinuation of dabigatran. Dabigatran should be applied with caution in elderly patients with renal insufficiency who also take drugs, which enhance the absorption of dabigatran.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - September 23, 2013 Category: Cardiology Authors: Josef Finsterer, Claudia Stöllberger, Gernot Paul, Adam Bastovansky Tags: Short Communication Source Type: research

Anticoagulation in Patients with Dilated Cardiomyopathy, Low Ejection Fraction, and Sinus Rhythm: Back to the Drawing Board
Summary Heart failure patients present an important thrombo‐embolic risk, including symptomatic or silent peripheral arterial embolism, pulmonary embolism, and stroke. Patients in sinus rhythm who have concomitant depressed (<35%) left ventricular ejection fraction have a 4% rate of embolic events. Several prospective randomized trials of anticoagulation in this group of patients were either underpowered or had a short period of follow‐up. Even though in two studies warfarin had a slight advantage over aspirin (in the WATCH and WARCEF trials), it was at the cost of an increased risk in major hemorrhage. To decrease ...
Source: Cardiovascular Therapeutics - September 12, 2013 Category: Cardiology Authors: Alexandru Nicolae Mischie, Valentin Chioncel, Ionel Droc, Crina Sinescu Tags: Short communication Source Type: research

Pages: 1  2